Tilmicosin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Tilmicosin
Accession Number
DB11471
Type
Small Molecule
Groups
Investigational, Vet approved
Description

Tilmicosin is a macrolide antibiotic. It is used in veterinary medicine for the treatment of bovine respiratory disease and ovine respiratory disease associated with Mannheimia haemolytica.

Structure
Thumb
Synonyms
  • Tilmicosin
External IDs
EL-870 / EL870 / LY-177370 / LY177370
Product Ingredients
IngredientUNIICASInChI Key
Tilmicosin phosphateSMH7U1S683137330-13-3NESIVXZOSKKUDP-ARVJLQODSA-N
International/Other Brands
Micotil
Categories
UNII
XL4103X2E3
CAS number
108050-54-0
Weight
Average: 869.147
Monoisotopic: 868.566040644
Chemical Formula
C46H80N2O13
InChI Key
JTSDBFGMPLKDCD-XVFHVFLVSA-N
InChI
InChI=1S/C46H80N2O13/c1-13-36-33(24-57-46-44(56-12)43(55-11)40(53)31(8)59-46)19-25(2)14-15-34(49)28(5)20-32(16-17-48-22-26(3)18-27(4)23-48)42(29(6)35(50)21-37(51)60-36)61-45-41(54)38(47(9)10)39(52)30(7)58-45/h14-15,19,26-33,35-36,38-46,50,52-54H,13,16-18,20-24H2,1-12H3/b15-14+,25-19+/t26-,27+,28-,29+,30-,31-,32+,33-,35-,36-,38+,39-,40-,41-,42-,43-,44-,45+,46-/m1/s1
IUPAC Name
(4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-{[(2R,3R,4S,5S,6R)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-7-{2-[(3R,5S)-3,5-dimethylpiperidin-1-yl]ethyl}-16-ethyl-4-hydroxy-15-({[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-5,9,13-trimethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione
SMILES
CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe serum concentration of (R)-warfarin can be increased when it is combined with Tilmicosin.
(S)-WarfarinThe serum concentration of (S)-Warfarin can be increased when it is combined with Tilmicosin.
3-isobutyl-1-methyl-7H-xanthineThe metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Tilmicosin.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Tilmicosin.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Tilmicosin.
7-DeazaguanineThe metabolism of 7-Deazaguanine can be decreased when combined with Tilmicosin.
7,9-DimethylguanineThe metabolism of 7,9-Dimethylguanine can be decreased when combined with Tilmicosin.
8-azaguanineThe metabolism of 8-azaguanine can be decreased when combined with Tilmicosin.
8-chlorotheophyllineThe metabolism of 8-chlorotheophylline can be decreased when combined with Tilmicosin.
9-DeazaguanineThe metabolism of 9-Deazaguanine can be decreased when combined with Tilmicosin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Mee JF, O'Farrell K: Tilmicosin and calf pneumonia. Vet Rec. 1991 May 11;128(19):460. [PubMed:1858280]
  2. McGuigan MA: Human exposures to tilmicosin (MICOTIL). Vet Hum Toxicol. 1994 Aug;36(4):306-8. [PubMed:7975134]
  3. Ziv G, Shem-Tov M, Glickman A, Winkler M, Saran A: Tilmicosin antibacterial activity and pharmacokinetics in cows. J Vet Pharmacol Ther. 1995 Oct;18(5):340-5. [PubMed:8587151]
  4. Zhang Y, Jiang H, Jin X, Shen Z, Shen J, Fu C, Guo J: Residue depletion of tilmicosin in chicken tissues. J Agric Food Chem. 2004 May 5;52(9):2602-5. [PubMed:15113165]
  5. Authors unspecified: Industry guidance on the administration of tilmicosin. Vet Rec. 2006 Aug 5;159(6):163. [PubMed:16924727]
  6. Von Essen S, Spencer J, Hass B, List P, Seifert SA: Unintentional human exposure to tilmicosin (Micotil 300). J Toxicol Clin Toxicol. 2003;41(3):229-33. [PubMed:12807303]
  7. Fodor L, Varga J, Gallowitsch F, Horvath-Papp I, Miklos G, Lajcsak A, Harmath A: Treatment of calf pneumonia with tilmicosin. Acta Vet Hung. 1993;41(1-2):41-9. [PubMed:8116500]
  8. Schumann FJ, Janzen ED, McKinnon JJ: Prophylactic medication of feedlot calves with tilmicosin. Vet Rec. 1991 Mar 23;128(12):278-80. [PubMed:2038809]
  9. Day FG: The value of tilmicosin in production medicine. J Am Vet Med Assoc. 1996 Mar 1;208(5):655-6. [PubMed:8617615]
  10. Atef M, Abo el-Sooud K, Nahed E, Tawfik M: Elimination of tilmicosin in lactating ewes. Dtsch Tierarztl Wochenschr. 1999 Jul;106(7):291-4. [PubMed:10481373]
External Links
KEGG Drug
D02492
ChemSpider
4445656
ChEMBL
CHEMBL1908333
Wikipedia
Tilmicosin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentLeukemia, Acute / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Disease1
1, 2RecruitingTreatmentLeukemia, Acute / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableRecruitingTreatmentHemiparesis / Hemiplegia / Strokes1
Not AvailableUnknown StatusTreatmentMajor Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0484 mg/mLALOGPS
logP3.34ALOGPS
logP4.19ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)12.55ChemAxon
pKa (Strongest Basic)10.16ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area186.15 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity232.21 m3·mol-1ChemAxon
Polarizability95.79 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Macrolides and analogues / O-glycosyl compounds / Monosaccharides / Piperidines / Oxanes / 1,2-aminoalcohols / Amino acids and derivatives / Carboxylic acid esters / Cyclic ketones / Lactones
show 11 more
Substituents
Aminoglycoside core / Macrolide / Glycosyl compound / O-glycosyl compound / Piperidine / Oxane / Monosaccharide / 1,2-aminoalcohol / Amino acid or derivatives / Carboxylic acid ester
show 24 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. [PubMed:11020135]

Drug created on February 25, 2016 12:01 / Updated on June 04, 2019 07:22